RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: RGN-259 Significantly Improves Signs and Symptoms of Severe Dry Eye in Phase 2 Clinical Trial
6/20/2012 10:02:05 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is reporting preliminary results from a double-masked, vehicle-controlled, physician-sponsored Phase 2 clinical trial evaluating RGN-259 for the treatment of severe dry eye. RGN-259 (Tß4 preservative-free eye drops) was found to be safe and well-tolerated and met key efficacy objectives with statistically significant sign and symptom improvements, compared to vehicle control, at various time intervals, including 28 days post-treatment.
comments powered by